Phase II clinical trial with long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) in patients with high risk neuroblastoma.

被引：0
|
作者：
Lode, Holger N.
Valteau-Couanet, Dominique
Troschke-Meurer, Sascha
Manzitti, Carla
Gray, Juliet
Castel, Victoria
Yaniv, Isaac
Loibner, Hans
Siebert, Nikolai
Glogova, Evgenia
Poetschger, Ulrike
Ladenstein, Ruth
机构：
[1] Univ Med Greifswald, Greifswald, Germany
[2] Univ Paris Sud, Inst Gustave Roussy, Pediat & Adolescent Oncol, Villejuif, France
[3] Gaslini Inst, Genoa, Italy
[4] Univ Southampton, Southampten, England
[5] Pediat Oncol Unit Hosp La Fe Valencia, Pediat Hematol & Oncol, Valencia, Spain
[6] Schneider Childrens Med Ctr Israel, Pediat Hematol Oncol, Petah Tiqwa, Israel
[7] Apeiron Biol AG, Vienna, Austria
[8] St Anna Kinderkrebsforschung eV, Vienna, Austria
[9] St Anna Childrens Canc Res Inst, Vienna, Austria
[10] St Anna Childrens Hosp & Res Inst, Paediat Haematol Oncol, SIOP Europe Neuroblastoma Grp, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.10562
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10562
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Long-Term Infusion of Anti-GD2 Antibody CH14.18/CHO in Combination with Interleukin-2 (IL2) in a Multicenter Phase II Clinical Trial in Patients with High Risk Neuroblastoma
    Lode, H.
    Valteau-Couanet, D.
    Siebert, N.
    Manzitti, C.
    Gray, J.
    Castel, V.
    Yaniv, I.
    Luksch, R.
    Laureys, G.
    Elliot, M.
    Michon, J.
    Owens, C.
    Trahair, T.
    Chan, G.
    Ruud, E.
    Schroeder, H.
    Beck-Popovic, M.
    Schreier, G.
    Loibner, H.
    Ladenstein, R.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S38 - S39
  • [2] Long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) activity and efficacy in high-risk relapsed/refractory neuroblastoma patients.
    Lode, Holger N.
    Valteau-Couanet, Dominique
    Garaventa, Alberto
    Gray, Juliet
    Castel, Victoria
    Yaniv, Isaac
    Siebert, Nikolai
    Jensen, Christian
    Endres, Stefanie
    Pill, Lena
    Eger, Christin
    Seidel, Diana
    Juettner, Madlen
    Kietz, Silke
    Ehlert, Karoline
    Janzek, Evelyne
    Loibner, Hans
    Mueller, Ina
    Ladenstein, Ruth L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma
    Ceylan, Kiraz
    Jahns, Luciana J.
    Lode, Bjoern N.
    Ehlert, Karoline
    Kietz, Silke
    Troschke-Meurer, Sascha
    Siebert, Nikolai
    Lode, Holger N.
    PEDIATRIC BLOOD & CANCER, 2018, 65 (06)
  • [4] Immune activation and clinical responses following long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in high-risk neuroblastoma patients.
    Lode, Holger N.
    Jensen, Christian
    Endres, Stefanie
    Pill, Lena
    Siebert, Nikolai
    Kietz, Silke
    Ehlert, Karoline
    Brock, Penelope
    Valteau-Couanet, Dominique
    Janzek, Evelyne
    Loibner, Hans
    Ladenstein, Ruth L.
    Mueller, Ina
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Immune activation, clinical response and survival following long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in high-risk neuroblastoma patients
    Lode, Holger
    Jensen, Christian
    Siebert, Nikolai
    Kietz, Silke
    Ehlert, Karoline
    Mueller, Ina
    Ladenstein, Ruth
    Janzek, Evelyne
    Loibner, Hans
    CANCER RESEARCH, 2014, 74 (19)
  • [6] Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO
    Mueller, Ina
    Ehlert, Karoline
    Endres, Stefanie
    Pill, Lena
    Siebert, Nikolai
    Kietz, Silke
    Brock, Penelope
    Garaventa, Alberto
    Valteau-Couanet, Dominique
    Janzek, Evelyne
    Hosten, Norbert
    Zinke, Andreas
    Barthlen, Winfried
    Varol, Emine
    Loibner, Hans
    Ladenstein, Ruth
    Lode, Holger N.
    MABS, 2018, 10 (01) : 55 - 61
  • [7] SURVIVAL FOLLOWING LONG-TERM INFUSION OF ANTI-GD2 ANTIBODY CH14.18/CHO IN COMBINATION WITH INTERLEUKIN-2 IN A PILOT COHORT OF HIGH-RISK NEUROBLASTOMA PATIENTS CORRELATES WITH FC-GAMMA RECEPTOR POLYMORPHISMS
    Lode, H. N.
    Jensen, C.
    Endres, S.
    Pill, L.
    Siebert, N.
    Brock, P.
    Valteau-Couanet, D.
    Loibner, H.
    Ladenstein, R.
    Mueller, I.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S122 - S122
  • [8] Pharmacokinetics (PK) of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.
    Desai, Ami Vijay
    Fox, Elizabeth
    DiSipio, Theresa C.
    Smith, L. Mary
    Lim, Allison
    Maris, John M.
    Balis, Frank M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] INTERLEUKIN-2 ADDS TOXICITY BUT NO MEASURABLE ACTIVITY IN RELAPSED/REFRACTORY NEUROBLASTOMA PATIENTS TREATED WITH LONG-TERM INFUSION OF ANTI GD2 ANTIBODY CH14.18/CHO
    Lode, H.
    Siebert, N.
    Eger, C.
    Schuster, M.
    Janzek, E.
    Loibner, H.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S224 - S224
  • [10] Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody
    Siebert, Nikolai
    Seidel, Diana
    Eger, Christin
    Juettner, Madlen
    Lode, Holger N.
    PLOS ONE, 2014, 9 (09):
12345